Vitestro Raises $70M to Advance Autonomous Blood Collection Robot

Vitestro has secured $70 million in Series B funding to support U.S. market entry of its autonomous blood collection device, Aletta, via the U.S. Food and Drug Administration de novo pathway.

Aletta combines robotics, artificial intelligence, and multimodal imaging to automate the full blood draw process—from vein identification to sample collection and bandaging. Using near-infrared and ultrasound imaging, the system locates veins and ensures accurate needle placement, aiming to improve consistency and reduce reliance on manual phlebotomy.

Backed by investors including Mayo Clinic and Labcorp, Vitestro plans to scale manufacturing, expand clinical trials, and enhance system integration. The device has already received CE marking and is undergoing limited use in Europe.

With comparable performance to manual methods, Aletta could help address staffing shortages and improve sample quality, positioning it as a potential new standard in diagnostic blood collection.

16-03-2026